JP7675502B2 - アルツハイマー病の治療用組成物および治療方法 - Google Patents

アルツハイマー病の治療用組成物および治療方法 Download PDF

Info

Publication number
JP7675502B2
JP7675502B2 JP2019563786A JP2019563786A JP7675502B2 JP 7675502 B2 JP7675502 B2 JP 7675502B2 JP 2019563786 A JP2019563786 A JP 2019563786A JP 2019563786 A JP2019563786 A JP 2019563786A JP 7675502 B2 JP7675502 B2 JP 7675502B2
Authority
JP
Japan
Prior art keywords
stat1
app
ch25h
mice
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520931A (ja
Inventor
フー シン－ユアン
Original Assignee
ジェネラス バイオファーマ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネラス バイオファーマ リミティド filed Critical ジェネラス バイオファーマ リミティド
Publication of JP2020520931A publication Critical patent/JP2020520931A/ja
Priority to JP2022143550A priority Critical patent/JP2022174207A/ja
Application granted granted Critical
Publication of JP7675502B2 publication Critical patent/JP7675502B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99038—Cholesterol 25-hydroxylase (1.14.99.38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019563786A 2017-05-16 2018-05-09 アルツハイマー病の治療用組成物および治療方法 Active JP7675502B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022143550A JP2022174207A (ja) 2017-05-16 2022-09-09 アルツハイマー病の治療用組成物および治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506782P 2017-05-16 2017-05-16
US62/506,782 2017-05-16
PCT/US2018/031901 WO2018213081A1 (en) 2017-05-16 2018-05-09 Compositions and methods for treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022143550A Division JP2022174207A (ja) 2017-05-16 2022-09-09 アルツハイマー病の治療用組成物および治療方法

Publications (2)

Publication Number Publication Date
JP2020520931A JP2020520931A (ja) 2020-07-16
JP7675502B2 true JP7675502B2 (ja) 2025-05-13

Family

ID=64274628

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563786A Active JP7675502B2 (ja) 2017-05-16 2018-05-09 アルツハイマー病の治療用組成物および治療方法
JP2022143550A Pending JP2022174207A (ja) 2017-05-16 2022-09-09 アルツハイマー病の治療用組成物および治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022143550A Pending JP2022174207A (ja) 2017-05-16 2022-09-09 アルツハイマー病の治療用組成物および治療方法

Country Status (9)

Country Link
US (1) US11873321B2 (https=)
EP (1) EP3628008A4 (https=)
JP (2) JP7675502B2 (https=)
KR (1) KR20200010311A (https=)
CN (2) CN111132694B (https=)
AU (1) AU2018270906B2 (https=)
CA (1) CA3063217A1 (https=)
TW (1) TW201900216A (https=)
WO (1) WO2018213081A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200010311A (ko) * 2017-05-16 2020-01-30 제네로스 바이오파마 리미티드 알츠하이머병의 치료를 위한 조성물 및 방법
CN111500694B (zh) * 2019-01-31 2023-02-24 中国科学院脑科学与智能技术卓越创新中心 Baz2b基因作为靶点在缓解衰老中的应用
JP2023521646A (ja) * 2020-03-31 2023-05-25 ウィルフレッド ジェフリーズ アルツハイマー病の治療方法
CA3259413A1 (en) * 2022-06-13 2023-12-21 The University Of Queensland USES OF JAK INHIBITORS IN THE MANAGEMENT OF DEPRESSION AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES ASSOCIATED WITH INFLAMMATION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
US20020188012A1 (en) * 1998-01-28 2002-12-12 Bisgaier Charles Larry Method for treating Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US8771700B2 (en) * 2006-08-23 2014-07-08 Rutgers, The State University Of New Jersey Interferon antagonists, antibodies thereto and associated methods of use
US9272029B2 (en) * 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
US9987224B2 (en) * 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
EP3140403A4 (en) * 2014-05-09 2017-12-20 Université Laval Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
ES2731437T3 (es) * 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
KR20200010311A (ko) * 2017-05-16 2020-01-30 제네로스 바이오파마 리미티드 알츠하이머병의 치료를 위한 조성물 및 방법

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
Balschun, D. et al., Interleukin-6: a cytokine to forget, The FASEB Journal, 2004, 発行日, Vol.18, No.14, p.1788-1790
Browne, T. C. et al., IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaq, The Journal of Immunology, 2013, 発行日, Vol.190, No.5, p.2241-2251
Devaux, P. et al., The measles virus phosphoprotein interacts with the linker domain of STAT1, Virology, 2013, 発行日, Vol.444, No.1-2, p.250-256
Elcioglu, H. K. et al., Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of stre, Molecular and Cellular Biochemistry, 2016, 発行日, Vol.420, No.1-2, p.21-28
Fassbender, K. et al., Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta, Proceedings of the National Academy of Sciences of the United States of America, 2001, 発行日, Vol.98, No.10, p.5856-5861
Hsu, W. L. et al., STAT1 negatively regulates spatial memory formation and mediates the memory-impairing effect of Aβ, Neuropsychopharmacology, 2014, 発行日, Vol.39, No.3, p.746-758
Jin, P. et al., Anti-inflammatory and anti-amyloidogenic effects of a small molecule, 2,4-bis(p-hydroxyphenyl)-2-but, Journal of Neuroinflammation, 2013, 発行日, 10:2
Matsumiya, T., Imaizumi, T., How are STAT1 and cholesterol metabolism associated in antiviral responses?, JAK-STAT, 2013, Vol.2,No.3, e24189, doi: 10.4161/jkst.24189
Murlidharan, G. et al., CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector, Molecular Therapy. Nucleic Acids, 2016, 発行日, Vol.5, No.7, e338
Papassotiropoulos, A. et al., Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disea, Neurodegenerative Diseases, 2005, 発行日, Vol.2, No.5, p.233-241
Park, W. et al., New perspectives of curcumin in cancer prevention, Cancer Prevention Research, 2013, 発行日, Vol.6, No.5, p.387-400
Peng, L. et al., Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody, mAbs, 2015, 発行日, Vol.7, No.2, p.428-439
Taylor, J. M. et al., Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease, Neurobiology of Aging, 2014, 発行日, Vol.35, No.5, p.1012-1023
Wu, Y. Y. et al., Alterations of the Neuroinflammatory Markers IL-6 and TRAIL in Alzheimer's Disease, Dementia and Geriatric Cognitive Disorders Extra, 2015, 発行日, Vol.5, No.3, p.424-434
Zhang, Y. Y. et al., Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid, Clinical Interventions in Aging, 2013, 発行日, Vol.8, p.103-110
天野 宏一, 臨床リウマチ医のための基礎講座 JAKとリウマチ性疾患, 臨床リウマチ, 2014, 発行日, 第26巻, 第4号, p.330-332
小野 賢二郎, 山田 正仁, Aβ凝集機序とその制御(解説), 医学のあゆみ, 2009, 発行日, 第229巻, 第5号, p.405-408

Also Published As

Publication number Publication date
EP3628008A4 (en) 2021-04-28
KR20200010311A (ko) 2020-01-30
CN119488598A (zh) 2025-02-21
JP2022174207A (ja) 2022-11-22
AU2018270906B2 (en) 2024-02-29
TW201900216A (zh) 2019-01-01
CN111132694A (zh) 2020-05-08
AU2018270906A1 (en) 2019-12-19
EP3628008A1 (en) 2020-04-01
US11873321B2 (en) 2024-01-16
CA3063217A1 (en) 2018-11-22
US20200199239A1 (en) 2020-06-25
CN111132694B (zh) 2024-12-03
WO2018213081A1 (en) 2018-11-22
JP2020520931A (ja) 2020-07-16

Similar Documents

Publication Publication Date Title
Dong et al. Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer’s disease
Neumann et al. The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Nicholatos et al. Nicotine promotes neuron survival and partially protects from Parkinson’s disease by suppressing SIRT6
Siman et al. The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy
Scuderi et al. Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti-inflammatory and neuroprotective effects
Haas et al. Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer’s disease
Rousseaux et al. TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau
JP2022174207A (ja) アルツハイマー病の治療用組成物および治療方法
George et al. The Alzheimer’s disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons
Lonskaya et al. Tyrosine kinase inhibition increases functional parkin‐Beclin‐1 interaction and enhances amyloid clearance and cognitive performance
Branchi et al. Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration
Polito et al. Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB
Westmark et al. FMRP mediates mGluR5-dependent translation of amyloid precursor protein
Tiwari et al. Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss
Della Sala et al. Synaptic plasticity and signaling in Rett syndrome
Lansdall An effective treatment for Alzheimer's disease must consider both amyloid and tau
Chen et al. Alzheimer’s amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway
Vijayan et al. A partial reduction of VDAC1 enhances mitophagy, autophagy, synaptic activities in a transgenic Tau mouse model
D’Alton et al. Therapeutic and diagnostic challenges for frontotemporal dementia
Lopez et al. Carbonic anhydrase inhibition ameliorates tau toxicity via enhanced tau secretion
US20210308077A1 (en) Combinations including beta-adrenoreceptor agonists for treatment of parkinson`s disease and movement disorders
Cisternas et al. Vascular amyloid accumulation alters the gabaergic synapse and induces hyperactivity in a model of cerebral amyloid angiopathy
Perez-Canamas et al. Fronto-temporal dementia risk gene TMEM106B has opposing effects in different lysosomal storage disorders
Schuld et al. Immunoproteasome deficiency protects in the retina after optic nerve crush
Rai et al. Suppression of leptin signaling reduces polyglucosan inclusions and seizure susceptibility in a mouse model for Lafora disease

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221006

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221011

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221118

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250417

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250428

R150 Certificate of patent or registration of utility model

Ref document number: 7675502

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150